This morning we watched Natera drop -8.4% to a price of $101.15 per share. The Large-Cap Medical Specialities company is now trading -19.15% below its average target price of $125.11. Analysts have set target prices ranging from $37.0 to $160.0 per share for Natera, and have given the stock an average rating of buy.
The stock has an average amount of shares sold short at 5.5%, and a short ratio of 5.99. The company's insiders own 3.59% of its outstanding shares, which indicates a strong alignment between management and shareholder interests. Finally, we also note that a significant number of institutional investors are invested in the stock, with 98.4% of Natera's shares being owned by this investor type.
Institutions Invested in Natera
| Date Reported | Holder | Percentage | Shares | Value |
|---|---|---|---|---|
| 2024-03-31 | Vanguard Group Inc | 9% | 11,044,743 | $1,117,175,771 |
| 2024-03-31 | JP Morgan Chase & Company | 6% | 7,357,916 | $744,253,214 |
| 2024-03-31 | Fred Alger Management, LLC | 5% | 6,546,927 | $662,221,676 |
| 2024-03-31 | Blackrock Inc. | 5% | 6,485,931 | $656,051,930 |
| 2024-03-31 | Farallon Capital Management LLC | 3% | 3,927,683 | $397,285,141 |
| 2024-03-31 | Ameriprise Financial, Inc. | 3% | 3,441,930 | $348,151,224 |
| 2024-03-31 | Invesco Ltd. | 3% | 3,210,099 | $324,701,518 |
| 2024-03-31 | State Street Corporation | 2% | 2,722,993 | $275,430,746 |
| 2024-03-31 | Millennium Management Llc | 2% | 2,639,254 | $266,960,546 |
| 2024-03-31 | Alliancebernstein L.P. | 2% | 2,619,459 | $264,958,281 |
Besides an analyst consensus of some upside potential, other market factors point to there being positive market sentiment on Natera.
